Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression

Englisch, Susanne; Jung, Hanna; Eisenacher, Sarah; Lewien, Antje; Becker, A.; Nowak, Ulrike; Braun, Hanna; Thiem, Jascha; Meyer‐Lindenberg, Andreas; Zink, Mathias

doi:10.1097/jcp.0000000000000909

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies have been done on hormone‐modulating drugs for the treatment of cognitive deficits in schizophrenia. Randomized controlled trials of rosiglitazone 80 an antidiabetic drug in the thiazolidinedione class, agomelatine 81 a novel and atypical antidepressant agent that acts as a melatonin receptor (MT 1 and MT 2 ) agonist and serotonergic (5HT 2C ) antagonist and intranasal insulin 82 and exenatide 83 did not demonstrate significant cognitive improvement.…”

Section: Resultsmentioning

confidence: 99%

Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review

Arsenault‐Mehta,

Hochman‐Bérard,

Johnson

et al. 2023

Neuropsychopharm Rep

View full text Add to dashboard Cite

BackgroundCognitive impairment are among the core features of schizophrenia, experienced by up to 75% of patients. Available treatment options for schizophrenia including dopamine antagonists and traditional antipsychotic medications have not been shown to confer significant benefits on cognitive deficits. Contrary to the focus on management of positive symptoms in schizophrenia, cognitive abilities are main predictor of independent living skills, functional abilities, employment, engagement in relapse prevention, and patients' subjective sense of well‐being and quality of life. This review aims to provide a summary of recent literature on pharmacological options for the treatment of cognitive deficits in schizophrenia.MethodsWe conducted a literature search of studies from 2011 to 2021 across four electronic databases including PubMed, PsycInfo, MEDLINE, and Embase. Human studies using a pharmacological treatment for cognitive impairment in schizophrenia were included.ResultsFifty‐eight eligible publications, representing 11 pharmacological classes, were included in this review. Major limitations involved small sample size, methodological limitations as well as heterogeneity of participants and outcome measures.ConclusionsOverall evidence remains inconclusive for any pharmacological classes studied for the treatment of cognitive deficits in schizophrenia. Methodological limitations in a majority of the studies rendered their findings preliminary. We further discuss possible explanations for these findings that could guide future research.

show abstract

Section: Resultsmentioning

confidence: 99%

Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review

Arsenault‐Mehta,

Hochman‐Bérard,

Johnson

et al. 2023

Neuropsychopharm Rep

View full text Add to dashboard Cite

show abstract

“…Средняя терапевтическая доза -25 мг/сут [33]. Агомелатин применяется для коррекции депрессивных и когнитивных расстройств у пациентов с шизофренией и перспективен для коррекции АИП [38,39].…”

Section: с е л е к т и в н ы е и м а о -вunclassified

Treatment of antipsychotic-induced parkinsonism in schizophrenic patients

Vaiman

Shnayder

Незнанов

et al. 2021

RJTAO

View full text Add to dashboard Cite

Antipsychotic-induced parkinsonism (AIP) is one of the prognostically unfavorable complications of psychopharmacotherapy in patients with schizophrenia. Many studies have investigated various drugs that are used to treat this neurological side effect. This review analyzes drugs that are used and may be perspective for the treatment of AIP. We searched for full-text publications in Russian and English in the following databases: E-Library, PubMed, Web of Science, Springer, using keywords and combined word searches over the past decade (2011—2020). The review covers drugs that are promising for the correction of AIP, including anticholinergic drugs; NMDA receptor antagonists; dopamine receptor agonists; selective inhibitors of monoamine oxidase B; catecholamine transferase inhibitors; melatonin preparations; melatonin receptor agonists; benzodiazepines; herbal preparations traditionally used for the prevention and correction of extrapyramidal syndrome of various etiologies. Currently, a small number of medications are used in clinical practice for the treatment of AIP. However, not all of them are registered in the Russian Federation. Along with the differences in the mechanisms of AIP pathogenesis in specific patients, the limited choice of AIP treatments makes it difficult to solve the problem of adverse neurological complications of psychopharmacotherapy in schizophrenia.

show abstract

Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Gαi-2-PKA-ASK1 signaling pathway

Lan

Zhang

et al. 2022

J Neuroinflammation

View full text Add to dashboard Cite

Background Agomelatine has been shown to be effective in the treatment of depression, but the molecular mechanisms underlying its antidepressant effects have yet to be elucidated. Identification of these molecular mechanisms would not only offer new insights into the basis for depression but also provide the foundation for the development of novel treatments for this disorder. Methods Intraperitoneal injection of LPS was used to induce depression-like behaviors in rats. The interactions of the 5-HT2C reporter and Gαi-2 were verified by immunoprecipitation or immunofluorescence assay. Inflammatory related proteins, autophagy related proteins and apoptosis markers were verified by immunoblotting or immunofluorescence assay. Finally, electron microscopy analysis was used to observe the synapse and ultrastructural pathology. Results Here, we found that the capacity for agomelatine to ameliorate depression and anxiety in a lipopolysaccharide (LPS)-induced rat model of depression was associated with an alleviation of neuroinflammation, abnormal autophagy and neuronal apoptosis as well as the promotion of neurogenesis in the hippocampal dentate gyrus (DG) region of these rats. We also found that the 5-HT2C receptor is coupled with G alphai (2) (Gαi-2) protein within hippocampal neurons and, agomelatine, acting as a 5-HT2C receptor antagonist, can up-regulate activity of the Gαi-2-cAMP-PKA pathway. Such events then suppress activation of the apoptosis signal-regulating kinase 1 (ASK1) pathway, a member of the mitogen-activated protein kinase (MAPK) family involved in pathological processes of many diseases. Conclusion Taken together, these results suggest that agomelatine plays a neuroprotective role in regulating neuroinflammation, autophagy disorder and apoptosis in this LPS-induced rat model of depression, effects which are associated with the display of antidepressant behaviors. These findings provide evidence for some of the potential mechanisms for the antidepressant effects of agomelatine. Graphical Abstract

show abstract

Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression

Cited by 4 publications

References 37 publications

Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review

Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review

Treatment of antipsychotic-induced parkinsonism in schizophrenic patients

Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Gαi-2-PKA-ASK1 signaling pathway

Contact Info

Product

Resources

About